Capital International Investors Reports 23.1M Shares of Royalty Pharma (RPRX)

Rhea-AI Filing Summary

Capital International Investors reports beneficial ownership of 23,111,998 shares of Royalty Pharma plc, representing 5.5% of the approximately 421,370,657 shares believed outstanding. CII is deemed the beneficial owner through its investment management entities and holds sole voting power for 23,006,820 shares and sole dispositive power for 23,111,998 shares. The filing is a Schedule 13G and the reporting person is classified as an investment adviser (IA). The statement certifies the position is held in the ordinary course of business and was not acquired to change or influence control of the issuer.

Positive

• Institutional ownership of 23,111,998 shares (5.5% of the class)
• Sole voting power for 23,006,820 shares and sole dispositive power for 23,111,998 shares

Negative

• None.

Insights

Financial Analyst

TL;DR: A material institutional passive stake of 5.5% is disclosed, confirming substantial ownership without intent to seek control.

Capital International Investors' Schedule 13G discloses beneficial ownership of 23,111,998 shares (5.5%) of Royalty Pharma. For investors, the scale of the position is noteworthy because a >5% holding by a large asset manager signals meaningful institutional interest. The filing also shows near-complete alignment between voting and dispositive power, with 23,006,820 shares under sole voting control and 23,111,998 shares under sole dispositive control.

The certification that the shares are held in the ordinary course and not to influence control frames this as a passive, portfolio stake rather than an activist position.

Corporate Governance Expert

TL;DR: Schedule 13G classification and the certification indicate a passive investor profile, not a control-seeking approach.

The filing classifies the reporting person as an investment adviser (IA) and is submitted on Schedule 13G, consistent with passive institutional ownership disclosures. The explicit certification in the filing states the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer," which reduces immediate governance concerns about an active campaign.

From a governance perspective, the record shows significant ownership that could matter in future votes, but no present indication of coordination or intent to alter control.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Royalty Pharma PLC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

G7709Q104

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G7709Q104

1

Names of Reporting Persons

Capital International Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 23,006,820.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 23,111,998.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

23,111,998.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Royalty Pharma PLC
(b)	Address of issuer's principal executive offices: 110 EAST 59TH STREET, NEW YORK, NY 10022
Item 2.
(a)	Name of person filing: Capital International Investors
(b)	Address or principal business office or, if none, residence: 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: G7709Q104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 23,111,998 ** **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 23,111,998 shares or 5.5% of the 421,370,657 shares believed to be outstanding.
(b)	Percent of class: 5.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 23,006,820
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 23,111,998
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital International Investors

Signature:	Jae Won Chung
Name/Title:	Vice President and Senior Counsel II, Capital Research and Management Company
Date:	08/12/2025

FAQ

How many RPRX shares does Capital International Investors beneficially own?

23,111,998 shares, representing 5.5% of the approximately 421,370,657 shares believed to be outstanding.

What voting and dispositive powers does CII hold over RPRX shares?

Sole voting power for 23,006,820 shares and sole dispositive power for 23,111,998 shares as reported in the filing.

What type of SEC filing did Capital International Investors submit for RPRX?

Schedule 13G, filed by a reporting person classified as an investment adviser (IA).

Is this stake intended to change or influence control of Royalty Pharma (RPRX)?

No. The filing certifies the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What is the date of the event that required this Schedule 13G filing?

The filing lists 06/30/2025 as the date of the event which requires filing of this statement.